Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α plus bevacizumab showed no clear difference in adverse events (grade ≥ 3) compared with standard targeted therapies (low certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Vaccine treatment showed no clear difference in 1‐year mortality compared with standard therapies (low certainty).
1 finding from 1 review
Quality of life · previously untreated patients with mRCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Vaccine treatment showed no clear difference in adverse events (grade ≥ 3) compared with standard therapies (low certainty).
1 finding from 1 review
QoL · previously untreated patients with mRCC
5 findings from 1 review
no estimate extracted
1 study · 730 participants
Low
no estimate extracted
1 study · 730 participants
Low
no estimate extracted
1 study · 730 participants
Low
Show 2 more findings
1‐year mortality · previously treated patients with mRCC
Targeted immunotherapy alone probably leads to lower 1‐year mortality compared with standard targeted therapies (moderate certainty).
1 finding from 1 review
Quality of life: improved to an important degree · previously treated patients with mRCC
Targeted immunotherapy alone probably leads to higher quality of life: Clinically relevant improvement in FKSI‐DRS compared with standard targeted therapies (moderate certainty).
2 findings from 1 review
Adverse events (grade ≥ 3) · previously treated patients with mRCC
Targeted immunotherapy alone probably leads to lower adverse events (grade ≥ 3) compared with standard targeted therapies (moderate certainty).
1 finding from 1 review
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Interferon‐α combined with targeted therapies showed no clear difference in 1‐year mortality compared with standard targeted therapy (moderate certainty).
1 finding from 1 review
Quality of life · previously untreated patients with mRCC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any outcome considered an indicator of change · mass media intervention for promoting healthy behaviours
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion smoking reduction, 3 months · mass media intervention for promoting healthy behaviours
1 finding from 1 review
Attempts to quit smoking · mass media intervention for promoting healthy behaviours
It is very uncertain whether targeted mass media intervention changes quit‐attempts, 3 months compared with general population mass media intervention (very low certainty).
1 finding from 1 review
Contemplation ladder to quit smoking (1‐10), 3 months · mass media intervention for promoting healthy behaviours
1 finding from 1 review
Adverse effects · mass media intervention for promoting healthy behaviours
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any outcome considered an adverse effect · mass media intervention for promoting healthy behaviours
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
At least 30% reduction in pain · people with cancer pain
1 finding from 1 review
At least 50% reduction in pain · people with cancer pain
1 finding from 1 review
Pain no worse than mild at one or two weeks (or equivalent) · people with cancer pain
1 finding from 1 review